Katy Amberley, BA, MA, Chief Executive, British Society for Haematology (BSH)
Jason Gardner, BSc, PhD, ISMPP CMPP™, Head of Scientific Services, CMC Connect, McCann Health Medical Communications
Maria Khan, BSc, Senior Editorial Director for Health Sciences, Wiley
Robert J. Matheis, PhD, MA, President and Chief Executive Officer, International Society for Medical Publication Professionals (ISMPP)
Alex Torre-Tasso, BA, Global Business Unit Head, Envision Pharma Group
Tyson Tu, PhD, Director, Global Medical Communications, Vertex
Chris Winchester, PhD, Chief Executive Officer, Oxford PharmaGenesis
Carolyn Hustad, PhD, Associate Vice President, Merck & Co., Inc.
The Coronavirus (COVID-19) pandemic has impacted nearly every facet of our personal and professional lives. Medical publication professionals are facing uncharted territory and uncertainty as to how long the impact will last.
With live congresses being cancelled, postponed or transitioned to a virtual format, we must now make decisions to convert presentations to virtual format, ensure embargo and copyright policies are followed, and actively update publication plans. Publications may face delays because authors and peer reviewers are focusing on clinical care, and also because of data availability delays.
Please join us to hear a panel of experts discuss their experiences and views, review our membership survey results, and present case studies to help guide professionals through this unprecedented situation.
At the end of this session, participants should be able to:
- Be knowledgeable of challenges to medical publishing stemming from the Coronavirus (COVID-19) pandemic
- Be aware of how congresses and journal publishers are being affected
- Modify publication plans appropriately in response to changing conditions
- Maintain good publication practices and ethics in a rapidly shifting environment